NASDAQ · NKTXHealthcarePharmaceuticals

Nkarta financials

$2.62−1.87%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$0.00$0.00$0.00$0.00——
Gross profit$0.00$0.00$0.00$0.00——
Gross margin——————
Operating income-$122.0M-$128.2M-$131.7M-$119.0M-$86.4M-$51.5M
Net income-$104.1M-$108.8M-$117.5M-$113.8M-$86.1M-$91.4M
Net margin——————
Diluted EPS$-1.41$-1.60$-2.40$-2.61$-2.62$-5.44
EBITDA-$112.8M-$119.0M-$125.8M-$116.3M-$84.7M-$50.7M
Operating cash flow-$88.7M-$99.7M-$86.2M-$57.0M-$67.9M-$43.5M
Free cash flow-$89.9M-$104.1M-$114.3M-$104.1M-$73.0M-$51.0M
Diluted shares74.0M67.9M49.0M43.6M32.9M16.8M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$39.6M$27.9M$31.0M$37.5M$60.8M$96.7M
Short-term investments$236.6M$239.5M$217.1M$314.6M$177.3M$218.2M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$404.2M$501.2M$378.9M$472.9M$273.9M$337.6M
Total liabilities$91.9M$93.2M$105.6M$100.7M$22.9M$16.4M
Shareholders' equity$312.3M$408.0M$273.3M$372.2M$251.0M$321.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology